The Lotus Valve System: an In-depth Review of the Technology
| Autor: | Matthew Seigerman, Saif Anwaruddin, Ashwin S. Nathan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Medtronic corevalve
medicine.medical_specialty Transcatheter aortic business.industry medicine.medical_treatment 030204 cardiovascular system & hematology Prosthesis Design United States Pacemaker implantation Transcatheter Aortic Valve Replacement 03 medical and health sciences 0302 clinical medicine Valve replacement Risk Factors Heart Valve Prosthesis Internal medicine medicine Cardiology Humans 030212 general & internal medicine Paravalvular leak Cardiology and Cardiovascular Medicine business Forecasting Edwards sapien |
| Zdroj: | Current Cardiology Reports. 21 |
| ISSN: | 1534-3170 1523-3782 |
| Popis: | Innovation for transcatheter aortic valve replacement (TAVR) has transformed a medically complex treatment into a standardized procedure. While Edwards SAPIEN and Medtronic CoreValve occupy the market for TAVR in the United States (US), additional valve systems are being developed. The Boston Scientific Lotus Valve system was recently FDA-approved and will represent the third valve in the US market. This evidence-based review will summarize advantages, disadvantages, and projected impact of this new TAVR system. The Lotus Valve system demonstrates superiority in terms of rates of paravalvular leak, with similar rates of mortality and disabling stroke. This benefit is at the expense of increased pacemaker implantation rates, though preliminary data from subsequent iterations of the Lotus Valve suggest decreasing rates over time. There is much anticipation from ongoing trials utilizing the Lotus Edge system, which may perform best for those with pre-existing pacemakers or anatomy that increases likelihood of paravalvular leak. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink